ライフサイエンスコーパス: dacarbazine

1 andard-of-care chemotherapy (temozolomide or dacarbazine).

2 s ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine).

3 2.0 months for nivolumab and 10.9 months for dacarbazine).

4 murafenib and 287 patients were treated with dacarbazine.

5 agents include doxorubicin, ifosfamide, and dacarbazine.

6 -up, adriamycin, bleomycin, vinblastine, and dacarbazine.

7 se rates were 48% for vemurafenib and 5% for dacarbazine.

8 w that it is no more effective than standard dacarbazine.

9 rs may potentiate the therapeutic effects of dacarbazine.

10 ne (BCNU), temozolomide, streptozotocin, and dacarbazine.

11 ted with the Dartmouth regimen compared with dacarbazine.

12 of doxorubicin, bleomycin, vinblastine, and dacarbazine.

13 nificantly superior OS and PFS compared with dacarbazine.

14 omly assigned, 269 to binimetinib and 133 to dacarbazine.

15 d eribulin and 218 (97%) of 224 who received dacarbazine.

16 th nivolumab and 17.6% of those treated with dacarbazine.

17 th those who initially received placebo plus dacarbazine.

18 ed to receive vemurafenib and 338 to receive dacarbazine.

19 d acquired resistance to B-Raf inhibition or dacarbazine.

20 on vemurafenib and 9.5 months (3.1-14.7) on dacarbazine.

21 er cycle, and tamoxifen 10 mg orally bid) or dacarbazine 1, 000 mg/m(2).

22 or investigator's choice chemotherapy (ICC; dacarbazine 1,000 mg/m(2) every 3 weeks or carboplatin a

23 o receive nivolumab 3 mg/kg every 2 weeks or dacarbazine 1,000 mg/m(2) every 3 weeks.

24 21-day cycle, patients received intravenous dacarbazine 1,000 mg/m(2) for a maximum of 16 cycles.

25 clophosphamide, vincristine, doxorubicin and dacarbazine (10 uM) demonstrated significant treatment e

26 n of nivolumab 3 mg/kg every 2 weeks or ICC (dacarbazine 1000 mg/m(2) every 3 weeks or paclitaxel 175

27 ther binimetinib 45 mg orally twice daily or dacarbazine 1000 mg/m(2) intravenously every 3 weeks.

28 inib (2 mg orally) once daily or intravenous dacarbazine (1000 mg per square meter of body-surface ar

29 r vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface ar

30 r vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg/m(2) of body surface area intraveno

31 g/m2 orally daily for 5 of every 28 days, or dacarbazine, 1000 mg/m2 intravenously every 21 days [inv

32 ith dacarbazine (median OS for trabectedin v dacarbazine, 12.4 v 12.9 months; hazard ratio, 0.87; P =

33 bulin (152 [67%]) than in those who received dacarbazine (126 [56%]), as were deaths (10 [4%] vs 3 [1

34 of doxorubicin, bleomycin, vinblastine, and dacarbazine; 143 PET-positive patients (PET score, 3 to

35 of doxorubicin, bleomycin, vinblastine, and dacarbazine (19%), or other regimens (13%).

36 PFS was also improved with eribulin versus dacarbazine (2.9 v 1.7 months, respectively; hazard rati

37 randomized to receive the Dartmouth regimen (dacarbazine 220 mg/m(2) and cisplatin 25 mg/m(2) days 1

38 eived combination cisplatin (25 mg/m2/d) and dacarbazine (220 mg/m2/d) on days 1 through 3 and 22 thr

39 , vinblastine 6 mg/m(2) (days 1 and 15), and dacarbazine 375 mg/m(2) (days 1 and 15), repeated on day

40 omycin 10 U/m(2), vinblastine 6 mg/m(2), and dacarbazine 375 mg/m(2)) intravenously on days 1 and 15

41 ody surface area, vinblastine 6 mg/m(2), and dacarbazine 375 mg/m(2)) or ABVD (doxorubicin 25 mg/m(2)

42 th dacarbazine (median PFS for trabectedin v dacarbazine, 4.2 v 1.5 months; hazard ratio, 0.55; P < .

43 n day 1, once every three weeks, followed by dacarbazine 400 mg/m(2) once on days 1 and 2, once every

44 ollowing: cisplatin 20 mg/m2 on days 1 to 4, dacarbazine 800 mg/m2 on day 1 only, vinblastine 1.6 mg/

45 .4 mg/m(2) intravenously on days 1 and 8) or dacarbazine (850 mg/m(2), 1000 mg/m(2), or 1200 mg/m(2)

46 .4 mg/m(2) intravenously on days 1 and 8) or dacarbazine (850, 1,000, or 1,200 mg/m(2) intravenously

47 cles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) alone or 6 cycles of ABVD followed by

48 ith doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) alone or to treatment with subtotal n

49 ls, doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and mechlorethamine, vincristine, pro

50 ing doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and Stanford V regimens in locally ex

51 of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and was labeled PET2.

52 and after 2 adriamycin-bleomycin-vinblastine-dacarbazine (ABVD) courses with (18)F-FDG PET, enrolled

53 of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) despite more adverse risk criteria am

54 of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by interim fluorodeoxyglucos

55 rom doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) for interim fluorodeoxyglucose positr

56 or doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in C studies; and VbM (reduced dose o

57 of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in previously untreated-according to

58 ith doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in the HAART era according to HIV ser

59 rubicin, bleomycin, vinblastine sulfate, and dacarbazine (ABVD) is associated with severe toxicity in

60 with adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or equivalent regimens, the 5-year FF

61 cles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) plus 20 Gy involved-field (IF)-RT to

62 ith doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) require radiotherapy.

63 rom doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) to bleomycin, etoposide, doxorubicin,

64 cles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) to guide treatment modification in a

65 ith doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) were enrolled retrospectively from ce

66 of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with an intensified chemotherapy regi

67 red doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with mechlorethamine, doxorubicin, vi

68 Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with or without radiation is standard

69 ard doxorubicin, bleomycin, vincristine, and dacarbazine (ABVD), followed by 30 Gy involved node radi

70 ved doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)-like chemotherapy.

71 ion doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).

72 of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).

73 of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).

74 ohort), or doxorubicin-bleomycin-vinblastine-dacarbazine (ABVD); in buccal DNA from five children of

75 2x doxorubicin, bleomycin, vinblastine, and dacarbazine [ABVD]; HD17: 2x escalated bleomycin, etopos

76 vedotin and nivolumab [AN] + doxorubicin and dacarbazine [AD]; AN+AD) may improve efficacy and safety

77 three preoperative cycles of doxorubicin and dacarbazine (ADIC), cyclophosphamide and ADIC (CyADIC),

78 as identical to COPP except that 250 mg/m(2) dacarbazine administered intravenously on days 1 to 3 re

79 = 252) at weeks 1, 4, 7, and 10 followed by dacarbazine alone every 3 weeks through week 22.

80 progression-free survival when compared with dacarbazine alone.

81 nt has proven to be superior to single agent dacarbazine alone.

82 Treatment with dacarbazine also increased stomach cancer risk (12 cases

83 Temozolomide, an oral analog of dacarbazine, also has activity against NETs when adminis

84 progression-free survival, as compared with dacarbazine, among previously untreated patients who had

85 ORR was 42% with nivolumab and 14% with dacarbazine; among patients alive at 5 years, ORR was 81

86 eribulin with that in patients who received dacarbazine (an active control).

87 ivolumab in combination with doxorubicin and dacarbazine (AN+AD) in patients with early-stage cHL.

88 of doxorubicin, bleomycin, vinblastine, and dacarbazine and diminishing use of radiotherapy is not w

89 Overall, Dacarbazine and Nifedipine photodegradations obeyed eta-

90 edian, 51.3 v 45.6 weeks in the placebo plus dacarbazine and sorafenib plus dacarbazine arms, respect

91 oved progression-free survival compared with dacarbazine and was tolerable.

92 BVD (adriamycin, bleomycin, vinblastine, and dacarbazine) and 30 Gy involved-field radiotherapy (IFRT

93 VD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and small-field radiotherapy is standard of

94 sks were seen for doxorubicin, dactinomycin, dacarbazine, and carmustine.

95 sed in vitro to increasing concentrations of dacarbazine, and dacarbazine-resistant cell lines SB2-D

96 n, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD) is highly effec

97 n, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD), we aimed to im

98 n, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone) has shown higher efficac

99 anomas to the alkylating drugs temozolomide, dacarbazine, and fotemustine.

100 This scheme of doxorubicin, dacarbazine, and nivolumab is feasible and well tolerate

101 However, replacing procarbazine with dacarbazine appears to mitigate gonadal and stem-cell to

102 umab with AVD (doxorubicin, vinblastine, and dacarbazine; APVD) for untreated CHL.

103 weeks versus 11.7 weeks in the placebo plus dacarbazine arm (hazard ratio [HR], 0.665; P = .068).

104 Median PFS in the sorafenib plus dacarbazine arm was 21.1 weeks versus 11.7 weeks in the

105 s; HR, 0.619) in favor of the sorafenib plus dacarbazine arm.

106 placebo plus dacarbazine and sorafenib plus dacarbazine arms, respectively; HR, 1.022).

107 ge, doxorubicin, bleomycin, vinblastine, and dacarbazine as initial therapy, and granulocyte colony-s

108 egimens in metastatic melanoma that included dacarbazine as the control arm, and which reported both

109 VD (doxorubicin, bleomycin, vinblastine, and dacarbazine) as compared with standard combined-modality

110 acarbazine-matched placebo every 3 weeks) or dacarbazine (at a dose of 1000 mg per square meter of bo

111 brolizumab and doxorubicin, vinblastine, and dacarbazine (AVD) chemotherapy.

112 approved with doxorubicin, vinblastine, and dacarbazine (AVD) for previously untreated stage III/IV

113 mbination with doxorubicin, vinblastine, and dacarbazine (AVD) is approved in the upfront setting for

114 tween ABVD and doxorubicin, vinblastine, and dacarbazine (AVD) now falls within the predefined noninf

115 dotin (BV) and doxorubicin, vinblastine, and dacarbazine (AVD).

116 ve cooperativity with the frontline regimens dacarbazine, B-Raf inhibition, and the anti-CTLA-4 antib

117 riamycin (doxorubicin)-bleomycin-vinblastine-dacarbazine-based therapy.

118 b vedotin with doxorubicin, vinblastine, and dacarbazine (BV+AVD) or nivolumab with doxorubicin, vinb

119 , dimethyl-triazeno-imidazole-carboxamide or dacarbazine, capecitabine or fluorouracil.

120 ubicin (Adriamycin), bleomycin, vinblastine, dacarbazine chemotherapy along with involved-field radio

121 ard doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy in the ongoing intergroup trial

122 ith doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy regimen since 2007, and 104 iPE

123 tandard doxorubicin, bleomycin, vinblastine, dacarbazine chemotherapy regimen, prescribed for nearly

124 of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy within a UK randomized trial of

125 VD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy is regarded as standard of car

126 VD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy, and then underwent an interim

127 ls have reported that the Dartmouth regimen (dacarbazine, cisplatin, carmustine, and tamoxifen) can i

128 either HDI or biochemotherapy consisting of dacarbazine, cisplatin, vinblastine, interleukin-2, IFN

129 h single-agent pembrolizumab, ipilimumab, or dacarbazine (control group), stratified according to the

130 f therapy with pembrolizumab, ipilimumab, or dacarbazine (control group), with randomization stratifi

131 s a robust surrogate for overall survival in dacarbazine-controlled randomised trials of metastatic m

132 Treatment of melanoma patients with dacarbazine could select for a more aggressive melanoma

133 338 patients initially randomly assigned to dacarbazine crossed over from dacarbazine to vemurafenib

134 igned to receive cisplatin, vinblastine, and dacarbazine (CVD) either alone or concurrent with interl

135 of chemotherapy (cisplatin, vinblastine, and dacarbazine [CVD]) with those of sequential biochemother

136 rth doxorubicin, bleomycin, vinblastine, and dacarbazine cycle and involved-field radiotherapy, and 4

137 ith doxorubicin, bleomycin, vinblastine, and dacarbazine; cyclophosphamide, vincristine, procarbazine

138 CVD consisted of dacarbazine (days 1 and 22) and cisplatin and vinblastin

139 ion regimen included cisplatin, vinblastine, dacarbazine, decrescendo interleukin-2 (IL-2), and inter

140 ximab vedotin, doxorubicin, vinblastine, and dacarbazine demonstrated improved overall survival compa

141 ng to presence of crossover, trial size, and dacarbazine dose.

142 clinically relevant chemotherapeutic drugs (dacarbazine, doxorubicin, paclitaxel, cisplatin, gemcita

143 y and preliminary efficacy of unesbulin plus dacarbazine (DTIC) in patients with advanced leiomyosarc

144 ineoplastic agents 5-fluorouracil (5-FU) and dacarbazine (DTIC) sensitize melanoma cells to lysis of

145 Patients crossed over to the dacarbazine (DTIC) treatment after disease progression f

146 erapy (results previously reported), BV plus dacarbazine (DTIC), and BV plus bendamustine.

147 the three-agent regimen of cisplatin (CDDP), dacarbazine (DTIC), and carmustine (BCNU) significantly

148 The combination of carmustine (BCNU), dacarbazine (DTIC), cisplatin (DDP), and tamoxifen (Tam)

149 d with matched control patients treated with dacarbazine (DTIC), median overall survival of 15.0 vers

150 ine brentuximab vedotin (BV; 1.8 mg/kg) with dacarbazine (DTIC; 375 mg/m2) (part B) or nivolumab (par

151 one (eBEACOPP) is increasingly replaced with dacarbazine (eBEACOPDac) to reduce toxicity.

152 By co-encapsulating immunogenic dacarbazine, Epacasome further enhances anti-tumor effec

153 py (doxorubicin, bleomycin, vinblastine, and dacarbazine; epirubicin, bleomycin, vinblastine, and pre

154 of nivolumab, doxorubicin, vinblastine, and dacarbazine followed by 30 Gy involved-site radiotherapy

155 was both more effective and less costly than dacarbazine followed by IPI then NIVO, or IPI followed b

156 of doxorubicin, bleomycin, vinblastine, and dacarbazine followed by RT is rare.

157 n (BV) and AVD (adriamycin, vinblastine, and dacarbazine) followed by 30 Gy involved site radiation t

158 rm the significant benefit of nivolumab over dacarbazine for all end points and add to the growing bo

159 of doxorubicin, bleomycin, vinblastine, and dacarbazine for Hodgkin disease (HD) and had undergone 4

160 b-ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for stage II-IV untreated classical Hodgkin

161 VD (doxorubicin, bleomycin, vinblastine, and dacarbazine), four escalated plus two standard cycles of

162 longer in the vemurafenib group than in the dacarbazine group (13.6 months [95% CI 12.0-15.2] vs 9.7

163 etinib group and 1.5 months (1.5-1.7) in the dacarbazine group (hazard ratio 0.62 [95% CI 0.47-0.80];

164 the nivolumab group versus 2.2 months in the dacarbazine group (hazard ratio for death or progression

165 red with 42.1% (95% CI, 33.0 to 50.9) in the dacarbazine group (hazard ratio for death, 0.42; 99.79%

166 ) compared with 7.6 months (6.1-16.6) in the dacarbazine group (HR 0.43 [95% CI 0.21-0.90]; p=0.024);

167 compared with 10.0 months (8.0-14.0) in the dacarbazine group (HR 0.75 [95% CI 0.60-0.93]; p=0.0085)

168 up versus 13.9% (95% CI, 9.5 to 19.4) in the dacarbazine group (odds ratio, 4.06; P<0.001).

169 the vemurafenib group and seven (2%) in the dacarbazine group had grade 5 events.

170 the binimetinib group vs none of 114 in the dacarbazine group), hypertension (20 [7%] vs two [2%]),

171 enib group and 64% (95% CI, 56 to 73) in the dacarbazine group.

172 nimetinib group and 25 (22%) patients in the dacarbazine group.

173 neutropenia (26 [9%] of 287 patients) in the dacarbazine group.

174 bocytopenia were increased in the oblimersen-dacarbazine group; however, there was no increase in ser

175 bleomycin sulfate, vinblastine sulfate, and dacarbazine) has been a frontline standard-of-care optio

176 VD (doxorubicin, bleomycin, vinblastine, and dacarbazine) has been established as the standard of car

177 ion on or after BCT (cisplatin, vinblastine, dacarbazine, IL-2 9 MU/m(2)/d for 4 days, and interferon

178 ed clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, m

179 ws: trabectedin in HG-MLPS; gemcitabine plus dacarbazine in LMS; high-dose prolonged-infusion ifosfam

180 superior disease control versus conventional dacarbazine in patients who have advanced liposarcoma an

181 se A phase III study comparing eribulin with dacarbazine in patients with advanced liposarcoma (LPS)

182 hase III trial to compare trabectedin versus dacarbazine in patients with advanced liposarcoma or lei

183 ed the efficacy and safety of sorafenib plus dacarbazine in patients with advanced melanoma.

184 the MEK inhibitor binimetinib versus that of dacarbazine in patients with advanced NRAS-mutant melano

185 fficacy and safety of eribulin compared with dacarbazine in patients with LPS, an independently rando

186 on of B-cell lymphoma 2 (Bcl-2) antisense to dacarbazine in the treatment of metastatic melanoma demo

187 VD (doxorubicin, bleomycin, vinblastine, and dacarbazine) in patients with stage III or IV classical

188 VD (doxorubicin, bleomycin, vinblastine, and dacarbazine) in PET2- and 4 x BEACOPP in PET2+ patients.

189 antibody blockade of netrin-1 combined with dacarbazine increased overall survival in several mouse

190 biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2 (IL-2), and interferon alfa a

191 ned in a 2:1 ratio to receive trabectedin or dacarbazine intravenously every 3 weeks.

192 Dacarbazine is considered the gold standard for treatmen

193 ditional survival benefit of ipilimumab plus dacarbazine is maintained with twice as many patients al

194 modified mesna, doxorubicin, ifosfamide, and dacarbazine [MAID]), interdigitated preoperative radiati

195 er kilogram of body weight every 2 weeks and dacarbazine-matched placebo every 3 weeks) or dacarbazin

196 to eribulin compared with those assigned to dacarbazine (median 13.5 months [95% CI 10.9-15.6] vs 11

197 f death in the trabectedin arm compared with dacarbazine (median OS for trabectedin v dacarbazine, 12

198 f disease progression or death compared with dacarbazine (median PFS for trabectedin v dacarbazine, 4

199 metastatic melanoma, interleukin (IL)-2 and dacarbazine, mediate objective response rates of 12% to

200 assigned to either trabectedin (n = 345) or dacarbazine (n = 173).

201 d 1:1 to receive ipilimumab at 10 mg/kg plus dacarbazine (n = 250) or placebo plus dacarbazine (n = 2

202 g plus dacarbazine (n = 250) or placebo plus dacarbazine (n = 252) at weeks 1, 4, 7, and 10 followed

203 total of 101 patients received placebo plus dacarbazine (n = 50) or sorafenib plus dacarbazine (n =

204 plus dacarbazine (n = 50) or sorafenib plus dacarbazine (n = 51).

205 nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD).

206 nivolumab plus doxorubicin, vinblastine, and dacarbazine (N-AVD) for newly diagnosed cHL.

207 mly assigned patients to eribulin (n=228) or dacarbazine (n=224).

208 ib was associated with risk reduction versus dacarbazine of both death and progression in patients wi

209 ents with melanoma who had been treated with dacarbazine, one of the most frequently used chemotherap

210 ith doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens (P =.7 by log-rank te

211 herapy composed of tamoxifen, cisplatin, and dacarbazine or this same chemotherapy followed by interf

212 of doxorubicin, bleomycin, vinblastine, and dacarbazine (or equivalent).

213 ycin, 6 mg/m(2) vinblastine, and 375 mg/m(2) dacarbazine) or AVD (ABVD modified regimen without the i

214 VD (doxorubicin, bleomycin, vinblastine, and dacarbazine), or both regimens, generally have a poor pr

215 l plus carboplatin, paclitaxel, carboplatin, dacarbazine, or oral temozolomide).

216 platinum II (cDDP, cis-platin), carboplatin, dacarbazine, or temozolomide together with velaparib, an

217 ne, doxorubicin, bleomycin, vinblastine, and dacarbazine; or standard BEACOPP (P = .0066).

218 2.8%) for patients treated with placebo plus dacarbazine (P = .002).

219 ath or disease progression, as compared with dacarbazine (P<0.001 for both comparisons).

220 S rates were 39% with nivolumab and 17% with dacarbazine; PFS rates were 28% and 3%, respectively.

221 ard doxorubicin, bleomycin, vinblastine, and dacarbazine (RABVD) in patients with classical Hodgkin l

222 the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen (ABVD) after two cycles of bleomycin

223 clophosphamide, vincristine, prednisone, and dacarbazine) regimen according to GPOH-HD2002 treatment

224 Dacarbazine remains the reference standard treatment for

225 The dacarbazine-resistant cell lines SB2-D and MeWo-D exhibi

226 ncreasing concentrations of dacarbazine, and dacarbazine-resistant cell lines SB2-D and MeWo-D were s

227 0.35 to 0.75; P < .001) with eribulin versus dacarbazine, respectively.

228 osure of primary cutaneous melanoma cells to dacarbazine resulted in the upregulation of interleukin-

229 In a previous study, dacarbazine showed selective in vitro toxicity to sinuso

230 kinase inhibitor vemurafenib, compared with dacarbazine, shows improved response rates, progression-

231 The addition of oblimersen to dacarbazine significantly improved multiple clinical out

232 Dacarbazine significantly reduced tumor size in these mi

233 the study (efficacy and toxicity analysis), dacarbazine substitution did not appear to compromise ef

234 tudies with azathioprine, monocrotaline, and dacarbazine suggested that toxins that cause HVOD initia

235 IC20-50) of DNA-damaging drugs (doxorubicin, dacarbazine, temozolamide) or antimitotic drugs (paclita

236 rior therapies for active disease, including dacarbazine/temozolomide or interleukin-2 (IL-2).

237 ie, doxorubicin, bleomycin, vinblastine, and dacarbazine) therapy.

238 and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.

239 ly assigned to dacarbazine crossed over from dacarbazine to vemurafenib.

240 duce doxorubicin, bleomycin, vinblastine and dacarbazine toxicity, the Cancer and Leukemia Group B co

241 ant nivolumab, doxorubicin, vinblastine, and dacarbazine treatment groups, respectively.

242 icity of the Dartmouth regimen with standard dacarbazine treatment in stage IV melanoma patients.

243 Compared with the first-line dacarbazine treatment strategy, NIVO followed by IPI pro

244 th Epo significantly increased resistance to dacarbazine treatment, and Epo increased the phosphoryla

245 %) for patients treated with ipilimumab plus dacarbazine versus 8.8% (95% CI, 5.7% to 12.8%) for pati

246 ximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin, bleomycin, vinbla

247 dified concurrent biochemotherapy regimen of dacarbazine, vinblastine, cisplatin, decrescendo IL-2, i

248 The response rate to dacarbazine was 10.2% compared with 18.5% for the Dartmo

249 Tumor response to two cycles of dacarbazine was assessed on the basis of tumor size in o

250 The survival benefit with nivolumab versus dacarbazine was observed across prespecified subgroups,

251 Sorafenib plus dacarbazine was well tolerated in patients with advanced

252 or single agent outpatient regimens, such as dacarbazine, which is usually not effective in patients

253 OS was 38% in patients randomly assigned to dacarbazine who had subsequent therapy, including nivolu

254 e hypothesize that combining doxorubicin and dacarbazine with nivolumab may enhance therapeutic effic

255 ith doxorubicin, bleomycin, vinblastine, and dacarbazine with or without radiation therapy, although

256 ing doxorubicin, bleomycin, vinblastine, and dacarbazine with the Stanford V regimen has been initiat

257 VD (doxorubicin, bleomycin, vinblastine, and dacarbazine) with IFRT.

258 how long-term exposure of melanoma cells to dacarbazine would affect their tumorigenic and metastati

259 omly assigned, the addition of oblimersen to dacarbazine yielded a trend toward improved survival at